Smart Chip System Used to Evaluate Homspera in Wound Healing Studies

WaferGen Biosystems, Inc. (OTCBB: WGBS), a leading developer of state-of-the-art genetic analysis systems, and IR BioSciences Holdings, Inc. (OTCBB:IRBS), a development-stage biotechnology company focused on the research, development and licensing of ImmuneRegen's wound healing drug candidate, Homspera, has announced the establishment of a novel wound healing research collaboration with the University of Texas Southwestern Medical Center. Under terms of the collaboration, UT Southwestern researchers will conduct preclinical and clinical studies to evaluate the efficacy of Homspera. As part of these studies, WaferGen's SmartChipT Real-Time PCR System will be used to understand the mechanism of action of Homspera. The collaborators believe that these studies may demonstrate the key role that the innovative capabilities of the SmartChip system can play in the field of drug development, particularly in validating relevant gene expression biomarkers and assessing their impact on patient response to treatment. Additionally, the studies are expected to provide ImmuneRegen with important data to support potential applications for Homspera in a range of therapeutic applications.